<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117829</url>
  </required_header>
  <id_info>
    <org_study_id>2016-1202</org_study_id>
    <nct_id>NCT03117829</nct_id>
  </id_info>
  <brief_title>Study: Diet and Exercise Study to Improve Brain Blood Flow: Blood Flow Improvement Trial</brief_title>
  <acronym>BFIT</acronym>
  <official_title>Diet and Exercise Trial to Improve Insulin Resistance, Increase Cerebral Blood Flow, Alter Metabolomic Biomarkers, and Decrease Alzheimer's Disease Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief Summary:

      Project Summary Metabolic syndrome (MetS) is associated with the development of diabetes and
      cardiovascular disease; however it is also linked with cognitive decline and dementia. The
      study investigators have shown that MetS is associated with lower cerebral blood flow (CBF)
      and memory function in late middle-aged adults at increased risk for developing Alzheimer's
      disease (AD). Insulin resistance (IR) is at the core of MetS, and a hallmark feature of IR is
      higher fasting blood glucose (FBG) as well as post prandial hyperglycemia.

      While the study investigators and others have demonstrated links between IR and CBF as well
      as cognition from an observational perspective, no studies have investigated CBF and
      cognition after an intervention involving exercise and a carbohydrate restricted diet (CRD)
      designed to improve or normalize IR and glucose homeostasis. The study investigators propose
      to determine the effect of improving or normalizing glucose homeostasis on CBF and cognition,
      through diet and exercise, in individuals with IR and at risk for the development of AD.

      While exercise and a CRD have been shown to improve IR and glycemic control, we have only
      limited knowledge of the mechanisms behind these improvements. Nutritional metabolomics, the
      global measurement and interpretation of metabolic profiles, assesses the interaction of diet
      with the endogenous gene-protein cascade and the gut microbiome. Additionally, exercise has
      been shown to have an impact on the human metabolome. Finally, numerous metabolites have been
      specifically linked to IR and impaired fasting glucose (IFG). The study investigators propose
      to use metabolomics to measure changes in metabolites as individuals normalize or improve IR
      and glucose homeostasis.

      Should this exploratory study reveal increased brain blood flow and improved memory in
      response to diet and exercise, then early treatment of these individuals at risk might offer
      new avenues for disease-course modification. Strategies towards early and effective risk
      factor management could be of value in reducing the risk of metabolic as well as cognitive
      decline. In addition, should this study reveal changes in metabolic abnormalities consistent
      with early indications of diabetes, metabolomics could be an effective approach to complement
      disease risk analysis in our goal toward precision care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:

      Research Strategy Design. The study investigators propose recruiting 40 middle-aged (45-65
      years) participants from the Wisconsin Alzheimer's Disease Research Center's (ADRC) &quot;IMPACT&quot;
      cohort to participate in a 12 week diet and exercise intervention with a 6-month follow-up.
      The Wisconsin ADRC has a special emphasis in preclinical AD, and participants are recruited
      with the expectation of being approached for intervention studies. Since the treatment will
      be applied to groups of 10 participants each, consisting of a total of 4 groups, the study
      investigators will not be able simultaneously to roll out the treatment program in all
      groups. Subsequently, an incomplete stepped wedge cluster randomized trial (SWCRT)48,49 will
      be considered. The design allows each block (intervention group) to be randomized to the
      intervention in a stepped fashion, initially providing a baseline measure, as indicate by '0'
      in the design matrix below, then followed by the 12 week intervention 'X' with '.' indicating
      no measurement, and '1a' indicating measurement post-12 week diet and exercise intervention
      and '1b' 6 months after the intervention.

      Time 1 Time 2 Time 3 Time 4 Time 5 Time 6 Time 7 Group 1 0 X 1a 1b . . . Group 2 . 0 X 1a 1b
      . . Group 3 . . 0 X 1a 1b . Group 4 . . . 0 X 1a 1b

      Timeline. It is anticipated that after recruitment and random assignment to one of the 4
      groups, baseline data collection and the 12 week intervention will begin for the first group
      in month 3 of the 24 month study. Baseline data collection will be completed for all groups
      by month 12, and post 12-week diet and exercise intervention data collection will be
      completed by month 15. Post 6 month follow-up data collection will be completed by month 20.
      The study investigators will share the results of baseline and follow-up findings in
      manuscripts and at national meetings, in addition to using the generated data to design a
      larger intervention trial.

      Participants. The study investigators will recruit 40 sedentary (exercise &lt;1 hour/week)
      participants who are 45-65 years of age, have impaired fasting glucose and are cognitively
      normal (based on the comprehensive ADRC battery). The cohort has received detailed annual
      medical and cognitive evaluation since enrolling in the Wisconsin ADRC. The cohort is
      well-characterized for health status and medication use, has undergone genotyping AD-related
      risk genes, and has banked fluid samples and DNA. Importantly, participants are characterized
      on metabolic risk, with slightly more than half meeting criteria for central obesity and/or
      elevated fasting glucose. Exclusion criteria are: active lifestyle (exercise &gt;1 hour/wk);
      body mass index &gt; 40; MRI contraindications; history of neurological disease, prior
      neurosurgery; diagnosed and/or treated type 1 or 2 diabetes; pregnancy; acute or subacute
      active cardiac disease (ongoing chest pain or myocardial infarction &lt; 3 months); significant
      orthopedic or musculoskeletal condition that limits weight bearing.

      Eligibility, Screening and Testing. Following IRB approval, a study coordinator will send an
      invitation letter describing the study to eligible participants previously identified via
      fasting glucose levels as pre-diabetic. Interested participants will be contacted by the
      study coordinator for further eligibility screening. Exercise testing will take place at the
      School of Nursing Exercise Physiology Laboratory. After an overnight fast, participants will
      arrive in the morning at the Clinical Research Unit to have blood samples collected for
      Metabolomics, A1C, glucose and insulin, receive cognitive testing, and magnetic resonance
      imaging (MRI). Participants will undergo MRI at the Wisconsin Institutes for Medical Research
      (WIMR).

      12-Week Diet and Exercise Intervention. The intervention is based on the research team's
      successful prior work in behavioral interventions. During the 12-week intervention, all
      participants will participate in a diet and exercise program. Exercise: Participants will
      attend a supervised exercise program, 10 subjects per group meeting 3x/wk. The program will
      begin with exercise for 20 minutes at a moderate intensity (determined during initial
      exercise testing). After week 2, exercise will be increased to 30 minutes; and after week 3,
      exercise will be increased to 50 minutes, resulting in 150 minutes of supervised exercise
      weekly. Exercise will be preceded by a 10 minute warm-up and a 10 minute cool down following
      exercise. The exercise classes will be held at the University of Wisconsin Natatorium (see
      letter of support), which includes stationary bikes, treadmills, elliptical machines, etc.
      Participants will be encouraged to exercise on their own for 30-50 minutes at least 2
      days/week for a total of 5 days/week of exercise. Participants will be provided with heart
      rate monitors and instruction on how to use them to maintain a target heart rate during
      exercise. Anaerobic threshold measured during baseline testing will be used initially to
      determine target heart rate, but participants will be monitored every other week during the
      exercise sessions using heart rate variability techniques published by the Co-PI, R.
      Gretebeck to adjust for improvements in exercise capacity54. Diet: Participants will be
      instructed by a dietitian (Co-PI, Dr. R. Gretebeck) to follow a diet designed to reduce post
      prandial and overall glucose levels. The American Diabetes Association approves the use of a
      CRD in overweight or obese individuals, but cautions that this approach should be limited to
      one year. There is no consensus on the definition of a CRD, but most studies have used diets
      providing between 30-100g of carbohydrates per day accompanied with a moderate amount of
      protein (15-30% of calories), with fats providing the rest of daily energy requirements. For
      this study, participants will be instructed to avoid or restrict grains, sugars, legumes,
      starchy vegetables, and fruits. Carbohydrate from dairy, condiments, nuts and seeds etc. will
      not be limited, resulting in a diet that is not considered severely restricted and thus
      easier to follow, but still less than 100g of carbohydrates per day. In concrete terms, most
      meals will include some source of animal protein including dairy products with non-starchy
      vegetables and fat from sources such as olive oil, avocado, nuts, butter and cheese. Behavior
      Change: The dietitian (who is also an exercise physiologist) and Co-I, K. Gretebeck, behavior
      change expert, will conduct a weekly 30-minute behavior change class with the focus on
      self-regulation (goal setting, self-monitoring, relapse prevention, overcoming barriers,
      etc.) to promote diet and exercise adherence. Specific emphasis will be placed on glucose
      self-monitoring for immediate feedback of glycemic control. Building on the behavior change
      classes, the study investigators will use glucose self-monitoring as an immediate feedback
      loop to motivate participants to maintain normalized or improved glucose homeostasis through
      diet and exercise. Following the 12-week diet and exercise intervention, participants will
      continue to self-monitor their blood glucose, and continue the diet and exercise program on
      their own. After the 12 week intervention, investigators will meet with participants monthly
      to collect blood and urine for metabolomics, and download the glucose history from the
      glucose monitors. The following objective measures will be used to assess adherence to the
      lifestyle intervention: history of glycemic control from glucose monitors, HOMA-IR, exercise
      capacity (V02 max), 6 minute walk, and metabolomic changes.

      Glucose Self-Monitoring. Participants will be provided with glucose monitors that maintain a
      history of results for fasting and post prandial blood glucose. During the first 2 weeks of
      the 12 week intervention, participants will be instructed to monitor their fasting and post
      prandial (evening meal) blood glucose daily, and after week 2 every other day, with the goal
      or reaching a FBG &lt;100 mg/dl (&lt;86 ideal), and 2 hour post-prandial blood glucose &lt;140 mg/dl
      (&lt;120 ideal). After the goal has been reached, participants will be asked to continue to
      self-monitor weekly. It is anticipated that many participants will reach this goal within the
      first 4 weeks.

      Primary Outcomes. CBF (measured at baseline, after the 12 week intervention and after 6 month
      follow-up). All participants will be screened for contraindications to MRI using standard
      clinical screening questionnaires. Participants will undergo MRI on a 3.0 Tesla X750 GE
      Discovery scanner with an 8-channel array head coil. Scan time is ~45 minutes and will
      include scans relevant to the primary outcome measure of micro- and macro-vessel CBF.
      Additional scans will include a 3D T1-weighted volume, and T2 FLAIR to assess ischemic lesion
      burden.

      Cognition (measured at baseline, after the 12 week intervention and after 6 month follow-up).
      Memory and executive function will be measured as follows: 1) Memory function as indexed by
      the California Verbal Learning Test-II: learning slope for trials 1-5 and long delay
      retention57, and 2) Executive function as indexed by: the Delis-Kaplan Executive Function
      System Trails Test, and Color-Word Interference Test58. Also, participants will be fully
      characterized on cognitive function by the ADRC, including the National Alzheimer's
      Coordinating Center Uniform Dataset.

      Metabolomics. Fasting blood and urine (second void of the morning) samples will be collected
      before and after the 12 week diet and exercise intervention as well as every 2 weeks during
      the 12 week intervention, and monthly during 6 month follow-up. Our project will use the
      metabolomics database developed at the NMRFAM at UW-Madison and made freely available through
      the BMRB59 at (www.bmrb.wisc.edu/metabolomics).

      Other Measures at baseline, after the 12 week intervention and after 6 month follow-up.

      Exercise Capacity (VO2max) will be measured using treadmill walking at 3.0 mph for 3 minute
      stages progressing potentially through 0, 3, 6, 9, 12, and 15% grades of incline. Every 3
      minutes the grade will be increased until the participants reach volitional fatigue. Heart
      rate and respiratory gases will be monitored continuously, and blood pressure and blood
      lactate (finger prick) will be monitored at the end of each stage.

      Physical Function (6 minute walk). Participants will be instructed to cover as much ground as
      possible on a hallway course over 6 minutes. 6 minute walk is measured in feet walked over 6
      minutes65.

      Metabolic Status. Fasting glucose, insulin, and A1c will be measured by University of WI
      Clinical Research Unit

      Diet and Exercise Self-efficacy and Self-regulation. Validated questionaires for
      self-regulation66 and self-efficacy67 for physical activity will be utilized, and a
      questionnaire developed by Anderson et. al.68 for nutrition related behavior will adapted for
      use with a CRD.

      Glucose Monitoring. Participants will receive a ReliOnÂ® Ultima (Abbott Diabetes Care Inc)
      glucose monitor and test strips, which meets FDA standards for accuracy (+20%). See
      description above for glucose self-monitoring. Data from the glucose monitors will be
      downloaded before, every 2 weeks during the 12 week intervention, and monthly for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain blood flow</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in brain blood flow from baseline to 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain blood flow</measure>
    <time_frame>6 months</time_frame>
    <description>Change on brain blood flow from post intervention to 6 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>Improve Brain Blood Flow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 week diet and exercise program to improve brain blood flow</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet and Exercise</intervention_name>
    <description>Diet and Exercise Study to Improve Brain Blood Flow</description>
    <arm_group_label>Improve Brain Blood Flow</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants from the Wisconsin Alzheimer's Disease Research Center (ADRC) -

        Exclusion Criteria:

          -  . Exclusion criteria are: active lifestyle (exercise &gt;1 hour/wk); body mass index &gt;
             40; MRI contraindications; history of neurological disease, prior neurosurgery;
             diagnosed and/or treated type 1 or 2 diabetes; pregnancy; acute or subacute active
             cardiac disease (ongoing chest pain or myocardial infarction &lt; 3 months); significant
             orthopedic or musculoskeletal condition that limits weight bearing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall J Gretebeck, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Randall Gretebeck, PhD</last_name>
    <phone>6082630927</phone>
    <email>rgretebeck@wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Bendlin</last_name>
    <email>bbb@medicine.wisc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randall Gretebeck</last_name>
      <phone>608-263-0927</phone>
      <email>rgretebeck@wisc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmrb.wisc.edu/metabolomics</url>
    <description>metabolomics database developed at the NMRFAM at UW-Madison and made freely available through the BMRB59</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

